Patents by Inventor Arthur A. Hurwitz

Arthur A. Hurwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200308246
    Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: March 3, 2020
    Publication date: October 1, 2020
    Inventors: Marc VAN DIJK, Ekaterina Vladimirovna BREOUS-NYSTROM, Alessandra FRANCHINO, Sébastien LALEVÉE, Andrew Arthur HURWITZ, Mark Adrian EXLEY, Benjamin Jacob WOLF
  • IMMUNE MODULATORS RELATING TO FOXO3A
    Publication number: 20130022640
    Abstract: The invention provides methods of enhancing an immune response to a cancer antigen in a mammal comprising inhibiting the activity of the foxo3a gene or gene product in dendritic cells in the mammal. The invention also provides methods of suppressing an immune response to an autoimmune disease antigen in a mammal comprising increasing the activity of the foxo3a gene or gene product in dendritic cells in the mammal. The invention also provides related methods of treating cancer and autoimmune diseases.
    Type: Application
    Filed: January 6, 2011
    Publication date: January 24, 2013
    Applicants: Secretary, Department of Health and Human Services
    Inventors: Arthur A. Hurwitz, Stephanie K. Watkins
  • Stimulation of T Cells Against Self-Antigens Using CTLA-4 Blocking Agents
    Publication number: 20090269353
    Abstract: Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation.
    Type: Application
    Filed: April 9, 2009
    Publication date: October 29, 2009
    Applicant: The Regents of the University of California
    Inventors: James P. ALLISON, Andrea Van Elsas, Arthur A. Hurwitz
  • Method of producing multicomponent lyophilized product
    Patent number: 4351158
    Abstract: At least two incompatible solutions are simultaneously charged into a container maintained at a temperature substantially below the freezing temperature of each solution in such predetermined amounts that the separate charges of solution freeze on the walls and are then lyophilized.
    Type: Grant
    Filed: January 22, 1980
    Date of Patent: September 28, 1982
    Assignee: American Home Products Corporation
    Inventors: Arthur Hurwitz, John Michelucci, John Krupey